• Sobi buyout breaks down

    Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

    By Dec. 3, 2021
  • Image attribution tooltip

    Novartis pays $150M for access to UCB's Parkinson's drug

    UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

    By Dec. 2, 2021
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK sets sights on brain diseases through Oxford partnership

    Equipped with $40 million in funding, a new institute from GSK and Oxford will initially focus on developing treatments for Alzheimer's, Parkinson's, ALS and other neurological conditions.

    By Dec. 2, 2021
  • Image attribution tooltip
    SciePro via Getty Images

    Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

    A $250 million acquisition of startup Lengo Therapeutics has given Blueprint a lung cancer drug that could compete with medicines from Takeda and J&J.

    By Nov. 29, 2021
  • GSK dives into NASH, RNA interference with Arrowhead deal

    GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people that has proven to be a tough target for drugmakers. 

    By , Nov. 23, 2021
  • Image attribution tooltip
    Getty Images

    Neurocrine stocks up on a biotech's psychiatric drugs

    A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders.

    By Nov. 22, 2021
  • Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead pays up to retain rights to Arcus cancer drugs

    The biotech will pay $725 million to opt into rights on four experimental medicines developed by Arcus, including ones that could challenge Merck's Keytruda in lung cancer.

    By Nov. 18, 2021
  • Image attribution tooltip
    Novo Nordisk

    Novo to acquire Dicerna for more than $3B amid RNA drug resurgence

    The acquisition would give Novo Nordisk ownership of one of the oldest and largest developers of RNA interference drugs, along with a web of potential royalty streams. 

    By Updated Nov. 18, 2021
  • Image attribution tooltip
    Permission granted by Biohaven Pharmaceuticals

    Pfizer buys into Biohaven's fast-selling migraine medicine

    The pharmaceutical giant will pay Biohaven $500 million for ex-U.S. rights to rimegepant — a sizable licensing deal, though not the buyout that some of the biotech's investors appeared to be hoping for.

    By Nov. 9, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Eye-focused gene therapy startup gets $60M cash infusion from Sanofi

    Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.  

    By Nov. 8, 2021
  • Image attribution tooltip

    Novartis to sell long-held stake in Roche for nearly $21B

    Novartis, which paid around $5 billion for its shares two decades ago, says it will gain about $14 billion from its sale and use the proceeds to further its current strategy.

    By Nov. 4, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments

    With an initial investment of $20 million, the collaboration will use technologies from various Flagship-backed companies to discover and develop new therapies for the disease.

    By Nov. 3, 2021
  • Image attribution tooltip
    Courtesy of Intellia Therapeutics

    Intellia looks to eye diseases in latest deal

    The gene editing company will take a 10% stake in SparingVision, a young biotech that will use Intellia's CRISPR technology to develop treatments for up to three ocular targets.

    By Oct. 13, 2021
  • Image attribution tooltip
    Getty Images

    Takeda takes aim at a biotech's gene therapy work

    For an upfront payment of $45 million, Takeda gains access to as many as eight programs from Poseida Therapeutics and a potential method of delivering gene therapies without the help of viruses.

    By Oct. 12, 2021
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Adamas, Flexion sell for $825M combined as biotech's dealmaking pace picks up

    After lagging for months, M&A has accelerated over the past five weeks. The latest evidence comes from two deals based largely on future drug sales.

    By Oct. 11, 2021
  • Image attribution tooltip

    Otsuka partners with Sunovion, Sumitomo in neurology drug pact

    Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs.

    By Kristin Jensen • Sept. 30, 2021
  • Image attribution tooltip
    Getty Images

    Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

    The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts of earlier-stage companies.

    By Updated Sept. 30, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Amicus, looking for a boost, sells its gene therapy work to a SPAC

    The value of the biotech's growing gene therapy portfolio has been "unrecognized" by investors, said CEO John Crowley, leading to a sudden shift for an initiative that began just three years ago.

    By Sept. 29, 2021
  • Image attribution tooltip
    Christopher Furlong via Getty Images

    AstraZeneca to buy rare disease drugmaker Caelum in small deal

    The British pharma inherited an option to acquire Caelum Biosciences when it bought Alexion last year. Caelum could receive as much as $500 million as a result of the planned buyout.

    By Kristin Jensen • Sept. 29, 2021
  • Image attribution tooltip

    AbbVie bets big on a gene therapy for eye diseases

    The company has agreed to pay $370 million, and possibly north of $1 billion more, to gain access to a Regenxbio treatment targeting wet AMD and other eye conditions.

    By Sept. 13, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi to buy Kadmon for $1.9B, extending deal streak

    The acquisition took some analysts by surprise as Sanofi has recently targeted specialty drugs, not general medicines like Kadmon's transplant treatment.

    By Sept. 8, 2021
  • Image attribution tooltip

    Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

    Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.

    By Sept. 7, 2021
  • Lilly puts more money into protein degradation

    The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics. 

    By Aug. 25, 2021
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

    The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.

    By Aug. 23, 2021
  • Illumina closes Grail takeover despite pending FTC trial

    The testing giant's decision to move ahead without sign-off from U.S. regulators and an EU investigation ongoing is a "maverick move," said Evercore analysts, as there's a chance Illumina may have to unwind the takeover.

    By Nick Paul Taylor • Aug. 19, 2021